Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

Bristol-Myers Squibb (BMS) building

BMS hails Opdivo and Yervoy combo in melanoma

New PD-1 therapy shines against the world’s first immunotherapy for skin cancer

- PMLiVE

BMS gives Erbitux rights to Lilly in the US

Firm wants to focus on its burgeoning PD-1 cancer range

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

- PMLiVE

AstraZeneca gains FDA orphan status for new cancer drug

Gains a longer patent life for the investigational lung disease drug

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

AstraZeneca and EHR firm to use drug alert system

Firm will team up with Practice Fusion to help keep patients on the right treatment pathway

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

Bristol-Myers Squibb (BMS) building

BMS buys into gene therapy with $1bn uniQure alliance

US firm on a deal spree in 2015 as it racks up yet another collaboration

Can Cinderella save us?

UK government warns over antibiotic resistant deaths

Cabinet Office document says the next 20 years is a crucial period for creating new medicines

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

UK Life Sciences Strategy - one year on

AstraZeneca joins Genomics England consortium

Combines with other pharma firms such as Illumina to utilise genetic data to create new medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links